ClinConnect ClinConnect Logo
Search / Trial NCT07073430

Evaluation of Artificial Intelligence System in Diagnosis of Colorectal Tubular Adenoma Lesions

Launched by RENMIN HOSPITAL OF WUHAN UNIVERSITY · Jul 9, 2025

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Colorectal Adenoma Artificial Intelligence (Ai) In Diagnosis

ClinConnect Summary

This clinical trial is studying a new way to help doctors detect and understand colorectal tubular adenomas, which are a type of growth in the colon that can sometimes lead to cancer. The study is testing an advanced computer system using artificial intelligence (AI) to analyze different types of images taken during colonoscopy exams. This AI system aims to support doctors by making accurate diagnoses and explaining how it reaches its decisions, which could improve treatment choices and make the process clearer for both doctors and patients.

People who need to have a colonoscopy and are 18 years or older can take part, as long as they agree to follow the study steps and sign a consent form. However, those with recent abdominal surgery, active severe bleeding in the lower digestive tract, certain inherited colon conditions, uncontrolled high blood pressure, heart or blood vessel diseases, pregnancy, or who cannot prepare their bowel properly for the colonoscopy, will not be eligible. Participants can expect to have their colonoscopy images included in building a special database that helps train the AI system. The study is currently recruiting, so if you meet the criteria and are interested, you might consider talking to your doctor about joining.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients aged ≥ 18 years, who need to undergo colonoscopy, regardless of gender.
  • Voluntarily sign the informed consent form
  • Promise to abide by the research procedures and cooperate in the implementation of the entire research process.
  • Exclusion Criteria:
  • Patients who has a history of abdominal or pelvic surgery or radiotherapy in the past;
  • Patients who has definite active lower gastrointestinal bleeding.
  • Existing or suspected hereditary colorectal polyposis, inflammatory bowel disease;
  • Uncontrolled hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 95 mmHg after standardized treatment)
  • There is a history of stroke, coronary artery disease, or vascular disease;
  • Pregnant;
  • Intestinal preparation cannot be carried out.

About Renmin Hospital Of Wuhan University

Renmin Hospital of Wuhan University is a leading healthcare institution in China, renowned for its commitment to advancing medical research and clinical innovation. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in various medical fields to facilitate cutting-edge studies aimed at improving patient outcomes and healthcare practices. With a strong emphasis on ethical standards and patient safety, Renmin Hospital collaborates with various stakeholders to drive forward-thinking research initiatives that contribute to the global medical community. Its state-of-the-art facilities and multidisciplinary teams enable efficient trial execution, ensuring robust data collection and analysis in pursuit of transformative healthcare solutions.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Trial Officials

Mingkai Chen, PHD

Principal Investigator

Renmin Hospital of Wuhan University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported